{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:27:15Z","timestamp":1760909235943},"reference-count":72,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"vor","delay-in-days":432,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The COVID-19 outbreak has resulted in collision between patients infected with SARS-CoV-2 and those with cancer on different fronts. Patients with cancer have been impacted by deferral, modification, and even cessation of therapy. Adaptive measures to minimize hospital exposure, following the precautionary principle, have been proposed for cancer care during COVID-19 era. We present here a consensus on prioritizing recommendations across the continuum of sarcoma patient care.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Material and Methods<\/jats:title>\n                  <jats:p>A total of 125 recommendations were proposed in soft-tissue, bone, and visceral sarcoma care. Recommendations were assigned as higher or lower priority if they cannot or can be postponed at least 2\u20133 months, respectively. The consensus level for each recommendation was classified as \u201cstrongly recommended\u201d (SR) if more than 90% of experts agreed, \u201crecommended\u201d (R) if 75%\u201390% of experts agreed and \u201cno consensus\u201d (NC) if fewer than 75% agreed. Sarcoma experts from 11 countries within the Sarcoma European-Latin American Network (SELNET) consortium participated, including countries in the Americas and Europe. The European Society for Medical Oncology-Magnitude of clinical benefit scale was applied to systemic-treatment recommendations to support prioritization.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>There were 80 SRs, 35 Rs, and 10 NCs among the 125 recommendations issued and completed by 31 multidisciplinary sarcoma experts. The consensus was higher among the 75 higher-priority recommendations (85%, 12%, and 3% for SR, R, and NC, respectively) than in the 50 lower-priority recommendations (32%, 52%, and 16% for SR, R, and NC, respectively).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The consensus on 115 of 125 recommendations indicates a high-level of convergence among experts. The SELNET consensus provides a tool for sarcoma multidisciplinary treatment committees during the COVID-19 outbreak.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2020-0516","type":"journal-article","created":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T15:59:41Z","timestamp":1600703981000},"page":"e1562-e1573","source":"Crossref","is-referenced-by-count":6,"title":["Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID-19 Pandemic"],"prefix":"10.1093","volume":"25","author":[{"given":"Javier","family":"Martin-Broto","sequence":"first","affiliation":[{"name":"Group of Advanced Therapies and Biomarkers in Sarcoma, Institute of Biomedicine of Seville (IBIS, HUVR, CSIC, Universidad de Sevilla), Sevilla, Spain"},{"name":"Department of Medical Oncology, University Hospital Virgen del Rocio, Seville, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Hindi","sequence":"additional","affiliation":[{"name":"Group of Advanced Therapies and Biomarkers in Sarcoma, Institute of Biomedicine of Seville (IBIS, HUVR, CSIC, Universidad de Sevilla), Sevilla, Spain"},{"name":"Department of Medical Oncology, University Hospital Virgen del Rocio, Seville, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Samuel","family":"Aguiar","sequence":"additional","affiliation":[{"name":"Department of Pelvic Surgery, A.C. Camargo Cancer Center, S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Badilla-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Department of medical oncology, Rafael \u00c1ngel Calder\u00f3n Guardia Hospital, San Jos\u00e9, Costa Rica"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Castro-Oliden","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Instituto Nacional de Enfermedades Neopl\u00e1sicas, Lima, Peru"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matias","family":"Chac\u00f3n","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Alexander Fleming Cancer Institute, Buenos Aires, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Correa-Generoso","sequence":"additional","affiliation":[{"name":"Radiotherapy Department, Virgen de la Victoria University Hospital, M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"\u00c1lava","sequence":"additional","affiliation":[{"name":"Pathology Department, University Hospital Virgen del Roc\u00edo, Seville, Spain"},{"name":"CIBERONC, Madrid, Spain"},{"name":"Department of Normal and Pathological Cytology and Histology, School of Medicine, University of Seville, Seville, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide Mar\u00eda","family":"Donati","sequence":"additional","affiliation":[{"name":"Unit of Orthopedic Pathology and Osteoarticular Tissue Regeneration, Rizzoli Orthopedic Institute, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikael","family":"Eriksson","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Skane University Hospital-Lund, Lund, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Falla-Jimenez","sequence":"additional","affiliation":[{"name":"Department of Breast and Soft Tissues Surgery, Instituto Nacional de Enfermedades Neopl\u00e1sicas, Lima, Peru"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gisela","family":"German","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Oncol\u00f3gico Provincial, C\u00f3rdoba, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Leticia","family":"Gobo Silva","sequence":"additional","affiliation":[{"name":"Department of Radiation Therapy, A.C. Camargo Cancer Center, S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francois","family":"Gouin","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Centre Le\u00f3n B\u00e9rard, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Gronchi","sequence":"additional","affiliation":[{"name":"Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Carlos","family":"Haro-Varas","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Instituto Nacional de Enfermedades Neopl\u00e1sicas, Lima, Peru"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Jim\u00e9nez-Brenes","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, San Vicente de Pa\u00fal Hospital, Heredia, Costa Rica"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Kasper","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Mannheim University Medical Center, Mannheim, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celso Abdon","family":"Lopes de Mello","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, A.C. Camargo Cancer Center, S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Maki","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Mart\u00ednez-Delgado","sequence":"additional","affiliation":[{"name":"Group of Advanced Therapies and Biomarkers in Sarcoma, Institute of Biomedicine of Seville (IBIS, HUVR, CSIC, Universidad de Sevilla), Sevilla, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hector","family":"Mart\u00ednez-Said","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Instituto Nacional de Cancerolog\u00eda, Mexico City, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge Luis","family":"Martinez-Tlahuel","sequence":"additional","affiliation":[{"name":"Department of Surgery, Instituto Nacional de Cancerolog\u00eda, Mexico City, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Manuel","family":"Morales-P\u00e9rez","sequence":"additional","affiliation":[{"name":"Radiology Department, University Hospital Virgen del Rocio, Seville, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Cristobal","family":"Mu\u00f1oz-Casares","sequence":"additional","affiliation":[{"name":"Department of Surgery, University Hospital Virgen del Rocio, Seville, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suely A.","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, A.C. Camargo Cancer Center, S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo Jose","family":"Ortiz-Cruz","sequence":"additional","affiliation":[{"name":"Orthopedic Surgery and Traumatology Department, La Paz University Hospital, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Palmerini","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Rizzoli Orthopedic Institute, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shreyaskumar","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Melanoma Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Moura","sequence":"additional","affiliation":[{"name":"Group of Advanced Therapies and Biomarkers in Sarcoma, Institute of Biomedicine of Seville (IBIS, HUVR, CSIC, Universidad de Sevilla), Sevilla, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Stacchiotti","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie Pierre","family":"Sunyach","sequence":"additional","affiliation":[{"name":"Department of Radiation Therapy, Centre Le\u00f3n B\u00e9rard, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia M.","family":"Valverde","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Vall d'Hebron Hospital, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Waisberg","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Alexander Fleming Cancer Institute, Buenos Aires, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Yves","family":"Blay","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centre Le\u00f3n B\u00e9rard, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,9,23]]},"reference":[{"key":"2021122511045188200_R1","doi-asserted-by":"crossref","first-page":"e641","DOI":"10.1016\/S2214-109X(20)30110-8","article-title":"COVID-19 in Italy: Momentous decisions and many uncertainties","volume":"8","author":"Lazzerini","year":"2020","journal-title":"Lancet Glob Health"},{"key":"2021122511045188200_R2","doi-asserted-by":"crossref","first-page":"102972","DOI":"10.1016\/j.critrevonc.2020.102972","article-title":"Cancer patients and research during COVID-19 pandemic: A systematic review of current evidence","volume":"150","author":"Moujaess","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"2021122511045188200_R3","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","article-title":"New insights into cancer immunoediting and its three component phases\u2013Elimination, equilibrium and escape","volume":"27","author":"Mittal","year":"2014","journal-title":"Curr Opin Immunol"},{"key":"2021122511045188200_R4","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1470-2045(09)70069-5","article-title":"Nosocomial infections in patients with cancer","volume":"10","author":"Kamboj","year":"2009","journal-title":"Lancet Oncol"},{"key":"2021122511045188200_R5","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: Consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"2021122511045188200_R6","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"2021122511045188200_R7","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41423-020-0401-3","article-title":"Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients","volume":"17","author":"Zheng","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"2021122511045188200_R8","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1470-2045(20)30096-6","article-title":"Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China","volume":"21","author":"Liang","year":"2020","journal-title":"Lancet Oncol"},{"key":"2021122511045188200_R9","volume-title":"OpenSAFELY: Factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. medRxiv","author":"Williamson","year":"2020"},{"key":"2021122511045188200_R10","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0140-6736(20)31173-9","article-title":"COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: A prospective cohort study","volume":"395","author":"Lee","year":"2020","journal-title":"Lancet"},{"key":"2021122511045188200_R11","doi-asserted-by":"crossref","first-page":"e936","DOI":"10.1634\/theoncologist.2020-0213","article-title":"A practical approach to the management of cancer patients during the novel coronavirus disease 2019 (COVID-19) pandemic: An international collaborative group","volume":"25","author":"Al-Shamsi","year":"2020","journal-title":"The Oncologist"},{"key":"2021122511045188200_R12","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2020.06.019","article-title":"Impact of the coronavirus disease 2019 pandemic on cancer treatment: The patients' perspective","volume":"136","author":"Joode","year":"2020","journal-title":"Eur J Cancer"},{"key":"2021122511045188200_R13","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41571-020-0362-6","article-title":"Cancer, COVID-19 and the precautionary principle: Prioritizing treatment during a global pandemic","volume":"17","author":"Hanna","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"2021122511045188200_R14","author":"Selnet"},{"key":"2021122511045188200_R15","volume-title":"COVID-19 rapid guidline: Delivery of radiotheraphy. National Institute for Health and Care Excellence"},{"key":"2021122511045188200_R16","volume-title":"ESMO-EURACAN Management and Treatment Adapted Recommendations in the COVID-19 Era: Sarcomas"},{"key":"2021122511045188200_R17","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2013.12.002","article-title":"Defining consensus: A systematic review recommends methodologic criteria for reporting of Delphi studies","volume":"67","author":"Diamond","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"2021122511045188200_R18","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1093\/annonc\/mdx310","article-title":"ESMO-Magnitude of Clinical Benefit Scale version 1.1","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann Oncol"},{"key":"2021122511045188200_R19","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/annonc\/mdv249","article-title":"A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)","volume":"26","author":"Cherny","year":"2015","journal-title":"Ann Oncol"},{"key":"2021122511045188200_R20","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1080\/000164701317323408","article-title":"Monitoring referral and treatment in soft tissue sarcoma: Study based on 1,851 patients from the Scandinavian Sarcoma Group Register","volume":"72","author":"Bauer","year":"2001","journal-title":"Acta Orthop Scand"},{"key":"2021122511045188200_R21","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/annonc\/mdt407","article-title":"Adherence to consensus-based diagnosis and treatment guidelines in adult soft-tissue sarcoma patients: A French prospective population-based study","volume":"25","author":"Mathoulin-P\u00e9lissier","year":"2014","journal-title":"Ann Oncol"},{"key":"2021122511045188200_R22","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/annonc\/mdh058","article-title":"Conformity to clinical practice guidelines, multidisciplinary management and outcome of treatment for soft tissue sarcomas","volume":"15","author":"Ray-Coquard","year":"2004","journal-title":"Ann Oncol"},{"key":"2021122511045188200_R23","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1245\/s10434-017-6003-3","article-title":"Adherence to Guidelines for Adult (Non-GIST) soft tissue sarcoma in The Netherlands: A plea for dedicated sarcoma centers","volume":"24","author":"Hoekstra","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"2021122511045188200_R24","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1634\/theoncologist.2018-0121","article-title":"Relevance of reference centers in sarcoma care and quality item evaluation: Results from the prospective registry of the Spanish Group for Research in Sarcoma (GEIS)","volume":"24","author":"Martin-Broto","year":"2019","journal-title":"The Oncologist"},{"key":"2021122511045188200_R25","doi-asserted-by":"crossref","first-page":"iv79","DOI":"10.1093\/annonc\/mdy310","article-title":"Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Casali","year":"2018","journal-title":"Ann Oncol"},{"key":"2021122511045188200_R26","doi-asserted-by":"crossref","first-page":"iv268","DOI":"10.1093\/annonc\/mdy321","article-title":"Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Casali","year":"2018","journal-title":"Ann Oncol"},{"issue":"Suppl 4","key":"2021122511045188200_R27","doi-asserted-by":"crossref","first-page":"iv68","DOI":"10.1093\/annonc\/mdy095","article-title":"Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Casali","year":"2018","journal-title":"Ann Oncol"},{"key":"2021122511045188200_R28","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1470-2045(20)30217-5","article-title":"Cancer guidelines during the COVID-19 pandemic","volume":"21","author":"Burki","year":"2020","journal-title":"Lancet Oncol"},{"key":"2021122511045188200_R29","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41591-020-0874-8","article-title":"Caring for patients with cancer in the COVID-19 era","volume":"26","author":"Haar","year":"2020","journal-title":"Nat Med"},{"key":"2021122511045188200_R30","volume-title":"COVID-19 rapid guideline: Delivery of systemic anticancer treatments. National Institute for Health and Care Excellence"},{"key":"2021122511045188200_R31","volume-title":"Resource for Management Options of Sarcoma During COVID-19. Society of Surgical Oncology"},{"key":"2021122511045188200_R32","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S1470-2045(20)30265-5","article-title":"Fewer cancer diagnoses during the COVID-19 epidemic in The Netherlands","volume":"21","author":"Dinmohamed","year":"2020","journal-title":"Lancet Oncol"},{"key":"2021122511045188200_R33","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/ACM.0000000000001092","article-title":"Is there a consensus on consensus methodology? Descriptions and recommendations for future consensus research","volume":"91","author":"Waggoner","year":"2016","journal-title":"Acad Med"},{"issue":"suppl 4","key":"2021122511045188200_R34","doi-asserted-by":"crossref","first-page":"iv51","DOI":"10.1093\/annonc\/mdy096","article-title":"Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Casali","year":"2018","journal-title":"Ann Oncol"},{"key":"2021122511045188200_R35","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1038\/bjc.2014.200","article-title":"What is the role of routine follow-up for localised limb soft tissue sarcomas? A retrospective analysis of 174 patients","volume":"110","author":"Rothermundt","year":"2014","journal-title":"Br J Cancer"},{"key":"2021122511045188200_R36","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1002\/ijc.31286","article-title":"Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG)","volume":"142","author":"Lindner","year":"2018","journal-title":"Int J Cancer"},{"key":"2021122511045188200_R37","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1080\/0284186X.2017.1330555","article-title":"Prediction of long-term survival in patients with metastatic gastrointestinal stromal tumor: Analysis of a large, single-institution cohort","volume":"56","author":"Hompland","year":"2017","journal-title":"Acta Oncol"},{"key":"2021122511045188200_R38","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s12032-013-0765-7","article-title":"What are the current outcomes of advanced gastrointestinal stromal tumors: Who are the long-term survivors treated initially with imatinib?","volume":"30","author":"Rutkowski","year":"2013","journal-title":"Med Oncol"},{"key":"2021122511045188200_R39","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa020890","article-title":"Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone","volume":"348","author":"Grier","year":"2003","journal-title":"N Engl J Med"},{"key":"2021122511045188200_R40","first-page":"48","volume-title":"First results of the EURO EWING 2012 (EE2012) trial comparing two chemotherapy regimens in newly diagnosed Ewing Sarcoma (ES). Poster presented at CTOS Annual meeting, Tokyo, Japan","author":"Wheatley","year":"2019"},{"key":"2021122511045188200_R41","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1200\/JCO.2011.40.3287","article-title":"Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: Long-term results from the International Society of Pediatric Oncology MMT95 study","volume":"30","author":"Oberlin","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122511045188200_R42","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(18)30337-1","article-title":"Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): A multicentre, open-label, randomised controlled, phase 3 trial","volume":"19","author":"Bisogno","year":"2018","journal-title":"Lancet Oncol"},{"key":"2021122511045188200_R43","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1200\/JCO.2001.19.5.1238","article-title":"Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: Results of the Italian randomized cooperative trial","volume":"19","author":"Frustaci","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122511045188200_R44","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/S1470-2045(17)30334-0","article-title":"Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): An international, open-label, randomised, controlled, phase 3, multicentre trial","volume":"18","author":"Gronchi","year":"2017","journal-title":"Lancet Oncol"},{"key":"2021122511045188200_R45"},{"key":"2021122511045188200_R46","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","article-title":"Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: A randomised, open-label, multicentre, phase 3 trial","volume":"387","author":"Sch\u00f6ffski","year":"2016","journal-title":"Lancet"},{"key":"2021122511045188200_R47","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1200\/JCO.2015.62.4734","article-title":"Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: Results of a phase III randomized multicenter clinical trial","volume":"34","author":"Demetri","year":"2016","journal-title":"J Clin Oncol"},{"key":"2021122511045188200_R48","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S1470-2045(15)70098-7","article-title":"Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: A randomised, open-label, phase 2 study","volume":"16","author":"Kawai","year":"2015","journal-title":"Lancet Oncol"},{"key":"2021122511045188200_R49","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"Graaf","year":"2012","journal-title":"Lancet"},{"key":"2021122511045188200_R50","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1200\/JCO.2010.33.6107","article-title":"Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: A Spanish Group for Research on Sarcomas study","volume":"29","author":"Garc\u00eda-Del-Muro","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122511045188200_R51","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1200\/JCO.2006.10.4117","article-title":"Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: Results of sarcoma alliance for research through collaboration study 002 [corrected]","volume":"25","author":"Maki","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122511045188200_R52","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1634\/theoncologist.2011-0467","article-title":"Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: A Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study)","volume":"17","author":"Pautier","year":"2012","journal-title":"The Oncologist"},{"key":"2021122511045188200_R53","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1023\/A:1008474802882","article-title":"Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: A study of the Spanish Group for Research on Sarcomas (GEIS)","volume":"9","author":"Buesa","year":"1998","journal-title":"Ann Oncol"},{"key":"2021122511045188200_R54","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/mpo.2950010109","article-title":"Adriamycin: A new effective agent in the therapy of disseminated sarcomas","volume":"1","author":"Benjamin","year":"1975","journal-title":"Med Pediatr Oncol"},{"key":"2021122511045188200_R55","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1200\/JCO.1987.5.1.21","article-title":"Adjuvant chemotherapy for osteosarcoma: A randomized prospective trial","volume":"5","author":"Eilber","year":"1987","journal-title":"J Clin Oncol"},{"key":"2021122511045188200_R56","doi-asserted-by":"crossref","first-page":"5888","DOI":"10.1002\/cncr.27651","article-title":"Long-term results (&gt;25\u2009years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma","volume":"118","author":"Bernthal","year":"2012","journal-title":"Cancer"},{"key":"2021122511045188200_R57","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1200\/JCO.2008.14.0095","article-title":"Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival\u2013A report from the Children's Oncology Group","volume":"26","author":"Meyers","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122511045188200_R58","first-page":"239","article-title":"cis-Dichlorodiammineplatinum (II) in advanced osteogenic sarcoma","volume":"62","author":"Ochs","year":"1978","journal-title":"Cancer Treat Rep"},{"key":"2021122511045188200_R59","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1023\/A:1008361612767","article-title":"A phase II study of cisplatin, ifosfamide and doxorubicin in operable primary, axial skeletal and metastatic osteosarcoma. European Osteosarcoma Intergroup (EOI)","volume":"10","author":"Voute","year":"1999","journal-title":"Ann Oncol"},{"key":"2021122511045188200_R60","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0959-8049(96)00439-X","article-title":"Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French Society of Paediatric Oncology","volume":"33","author":"Gentet","year":"1997","journal-title":"Eur J Cancer"},{"key":"2021122511045188200_R61","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/pbc.20228","article-title":"High-dose ifosfamide in relapsed pediatric osteosarcoma: Therapeutic effects and renal toxicity","volume":"44","author":"Berrak","year":"2005","journal-title":"Pediatr Blood Cancer"},{"key":"2021122511045188200_R62","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S1470-2045(14)71136-2","article-title":"Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial","volume":"16","author":"Grignani","year":"2015","journal-title":"Lancet Oncol"},{"key":"2021122511045188200_R63","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S1470-2045(18)30742-3","article-title":"Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: A non-comparative, randomised, double-blind, placebo-controlled, phase 2 study","volume":"20","author":"Duffaud","year":"2019","journal-title":"Lancet Oncol"},{"key":"2021122511045188200_R64","doi-asserted-by":"crossref","first-page":"11007a","DOI":"10.1200\/JCO.2019.37.15_suppl.11007","article-title":"Results of the first interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma","volume":"37","author":"McCabe","year":"2019","journal-title":"J Clin Oncol"},{"key":"2021122511045188200_R65","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/bjc.2017.252","article-title":"GEIS-21: A multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: A report from the Spanish sarcoma group (GEIS)","volume":"117","author":"Mora","year":"2017","journal-title":"Br J Cancer"},{"key":"2021122511045188200_R66","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/pbc.22596","article-title":"Prolonged 14-day continuous infusion of high-dose ifosfamide with an external portable pump: Feasibility and efficacy in refractory pediatric sarcoma","volume":"55","author":"Meazza","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"2021122511045188200_R67","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/jama.2012.347","article-title":"One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: A randomized trial","volume":"307","author":"Joensuu","year":"2012","journal-title":"JAMA"},{"key":"2021122511045188200_R68","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/S0140-6736(01)06535-7","article-title":"Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study","volume":"358","author":"Oosterom","year":"2001","journal-title":"Lancet"},{"key":"2021122511045188200_R69","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"key":"2021122511045188200_R70","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1158\/1078-0432.CCR-11-3005","article-title":"Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure","volume":"18","author":"Demetri","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2021122511045188200_R71","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","article-title":"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): An international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Demetri","year":"2013","journal-title":"Lancet"},{"issue":"suppl 5","key":"2021122511045188200_R72","first-page":"v851","article-title":"INVICTUS: A phase 3, interventional, double-blind, placebo-controlled study to assess the safety and efficacy of ripretinib as 4th-line therapy in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior anticancer therapies (nct03353753)","volume":"30","author":"Mehren","year":"2019","journal-title":"Ann Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1634%2Ftheoncologist.2020-0516","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2020-0516","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2020-0516","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/10\/e1562\/41921016\/oncolo_25_10_e1562.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/10\/e1562\/41921016\/oncolo_25_10_e1562.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T11:07:11Z","timestamp":1640430431000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/25\/10\/e1562\/6443985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,23]]},"references-count":72,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,9,23]]},"published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2020-0516","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,10,1]]},"published":{"date-parts":[[2020,9,23]]}}}